Sangui BioTech International Inc.
- WKN: 906757
- ISIN: US80105B1017
- Land: Germany
Nachricht vom 14.05.2019 | 09:42
Sangui BioTech International Inc.: Sales of USD 63,429 in the first nine month
DGAP-News: Sangui BioTech International Inc. / Key word(s): 9 Month figures
- Sales of USD 63,429 in the first nine month
While royalty income in the first half of the year were still higher than in the previous year, royalty income in the third quarter were USD 2,129 lower than in the same period of the previous year. Despite the strong end-of-year business in 2018, royalty income in the first three quarters therefore declined by USD 1,844 or 3% compared to the previous year.
As operating expenses increased USD 48,062 or 20% to USD 291,214 during the period, nine month operating loss increased USD 49,862 to USD 227,785 from the prior year. The operating loss for the third quarter of 2019, on the other hand, increased disproportionately by USD 5,352 compared to the previous year to USD 74,150.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Sangui BioTech International Inc.: Practitione ...
Sangui BioTech International Inc.: Lower reven ...
Sangui BioTech International secures financial ...
Sangui BioTech International Inc.: Series of p ...
Sangui BioTech International Inc.: Revenues sl ...
MBH Corporation. Hohes Kurspotenzial
Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor
Der AKTIONÄR News
02. April 11:55 K+S: Short-Squeeze läuft - Aktie steigt 8%
02. April 11:46 Carl Zeiss Meditec: Aktie rutscht erneut massiv ab – was nun?
02. April 11:44 Gold: Starinvestor warnt!
02. April 11:40 Zur Rose und Shop Apotheke: Da kommt etwas Großes auf uns zu
News im Fokus
Fresenius Medical Care kooperiert mit anderen Dialyseanbietern zur Bekämpfung der Coronavirus-Pandemie in den USA
01. April 2020, 09:01
Fourth Quarter Fiscal Year 2020 Results
06. April 2020
Original-Research: Valneva SA (von First Berlin Equity Research GmbH): Kaufen Valneva SA
02. April 2020